Home › NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RecruitingPhase 2/3
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Key Inclusion Criteria: • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility Key Exclusion Criteria: • Hypersensitivity to investigational medicinal product or to any of its excipients Other protocol defined Inclusion/Exclusion criteria will apply
About the study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
What is being tested
- Povetacicept (drug)
- Tacrolimus (drug)
Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 176 · Started: Sep 30, 2025
Contact the study team
- Medical Information · Phone: 001-617-341-6777
Official record on ClinicalTrials.gov — NCT07204275
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.